Alpine Immune Sciences, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 32.18 million compared to USD 57.76 million a year ago. Basic loss per share from continuing operations was USD 0.64 compared to USD 1.73 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
64.96 USD | -0.02% | +0.22% | +240.82% |
May. 10 | Alpine Immune Sciences, Vertex Pharmaceuticals Deal Crosses Another Milestone | MT |
May. 09 | Alpine Immune Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+240.82% | 4.46B | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- ALPN Stock
- News Alpine Immune Sciences, Inc.
- Alpine Immune Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023